- Home
- NGG vs REGN Comparison
NGG vs REGN Comparison
Compare NGG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGG
- REGN
- Stock Information
- Founded
- NGG 1990
- REGN 1988
- Country
- NGG United Kingdom
- REGN United States
- Employees
- NGG N/A
- REGN N/A
- Industry
- NGG Natural Gas Distribution
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NGG Utilities
- REGN Health Care
- Exchange
- NGG Nasdaq
- REGN Nasdaq
- Market Cap
- NGG 71.4B
- REGN 63.4B
- IPO Year
- NGG 1999
- REGN 1991
- Fundamental
- Price
- NGG $74.73
- REGN $589.92
- Analyst Decision
- NGG Hold
- REGN Buy
- Analyst Count
- NGG 2
- REGN 23
- Target Price
- NGG N/A
- REGN $905.22
- AVG Volume (30 Days)
- NGG 1.0M
- REGN 1.4M
- Earning Date
- NGG 06-03-2025
- REGN 04-29-2025
- Dividend Yield
- NGG 7.56%
- REGN 0.30%
- EPS Growth
- NGG N/A
- REGN 16.49
- EPS
- NGG 0.79
- REGN 39.43
- Revenue
- NGG $23,744,492,829.00
- REGN $14,085,700,000.00
- Revenue This Year
- NGG $5.80
- REGN N/A
- Revenue Next Year
- NGG $12.36
- REGN $6.97
- P/E Ratio
- NGG $19.23
- REGN $15.12
- Revenue Growth
- NGG N/A
- REGN 7.52
- 52 Week Low
- NGG $55.13
- REGN $520.50
- 52 Week High
- NGG $74.82
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- NGG 61.14
- REGN 49.26
- Support Level
- NGG $72.36
- REGN $564.91
- Resistance Level
- NGG $73.96
- REGN $617.52
- Average True Range (ATR)
- NGG 0.99
- REGN 21.07
- MACD
- NGG 0.17
- REGN 4.42
- Stochastic Oscillator
- NGG 91.13
- REGN 68.35
About NGG National Grid Transco PLC National Grid PLC (NEW)
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).